SBI Healthcare Opportunities Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (24-Jul-24)
Returns (Since Inception)
Fund Overview
Fund Size
₹2,760 Cr
Expense Ratio
0.94%
ISIN
INF200K01UP2
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
01 Jan 2013
About this fund
As of 24-Jul-24, it has a Net Asset Value (NAV) of ₹418.34, Assets Under Management (AUM) of 2760.05 Crores, and an expense ratio of 0.94%.
- SBI Healthcare Opportunities Fund Direct Growth has given a CAGR return of 18.26% since inception.
- The fund's asset allocation comprises around 98.36% in equities, 0.00% in debts, and 1.64% in cash & cash equivalents.
- You can start investing in SBI Healthcare Opportunities Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+38.05%
+45.90% (Cat Avg.)
3 Years
+17.23%
+14.66% (Cat Avg.)
5 Years
+29.49%
+26.30% (Cat Avg.)
10 Years
+15.91%
+16.02% (Cat Avg.)
Since Inception
+18.26%
— (Cat Avg.)
Portfolio Summaryas of 30th June 2024
| Equity | ₹2,714.83 Cr | 98.36% |
| Others | ₹45.22 Cr | 1.64% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹380.21 Cr | 13.78% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹211.65 Cr | 7.67% |
| Divi's Laboratories Ltd | Equity | ₹183.86 Cr | 6.66% |
| Cipla Ltd | Equity | ₹183.62 Cr | 6.65% |
| Lonza Group Ltd ADR | Equity | ₹136.45 Cr | 4.94% |
| Aether Industries Ltd | Equity | ₹129.14 Cr | 4.68% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹112.53 Cr | 4.08% |
| Aurobindo Pharma Ltd | Equity | ₹108.68 Cr | 3.94% |
| Mankind Pharma Ltd | Equity | ₹106.46 Cr | 3.86% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹104.22 Cr | 3.78% |
| Abbott India Ltd | Equity | ₹99.45 Cr | 3.60% |
| Gland Pharma Ltd | Equity | ₹98.54 Cr | 3.57% |
| Lupin Ltd | Equity | ₹97.28 Cr | 3.52% |
| Torrent Pharmaceuticals Ltd | Equity | ₹83.74 Cr | 3.03% |
| Rainbow Childrens Medicare Ltd | Equity | ₹74.75 Cr | 2.71% |
| Alkem Laboratories Ltd | Equity | ₹69.42 Cr | 2.52% |
| Global Health Ltd | Equity | ₹67.85 Cr | 2.46% |
| Ami Organics Ltd | Equity | ₹67.75 Cr | 2.45% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹62.4 Cr | 2.26% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹61.41 Cr | 2.23% |
| Fortis Healthcare Ltd | Equity | ₹57.04 Cr | 2.07% |
| Zydus Lifesciences Ltd | Equity | ₹53.7 Cr | 1.95% |
| Treps | Cash - Repurchase Agreement | ₹50.28 Cr | 1.82% |
| Laurus Labs Ltd | Equity | ₹44.58 Cr | 1.62% |
| Dr. Lal PathLabs Ltd | Equity | ₹41.71 Cr | 1.51% |
| Gufic Biosciences Ltd | Equity | ₹34.64 Cr | 1.25% |
| Suven Pharmaceuticals Ltd | Equity | ₹27.59 Cr | 1.00% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹14.98 Cr | 0.54% |
| Net Receivable / Payable | Cash - Collateral | ₹-5.06 Cr | 0.18% |
| Sanofi India Ltd | Equity | ₹0.76 Cr | 0.03% |
| Sanofi Consumer He | Equity | ₹0.44 Cr | 0.02% |
Allocation By Market Cap (Equity)
Large Cap Stocks
38.92%
Mid Cap Stocks
28.83%
Small Cap Stocks
30.59%
Allocation By Credit Quality (Debt)
A
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹2,517.5 Cr | 91.21% |
| Basic Materials | ₹196.89 Cr | 7.13% |
Risk & Performance Ratios
Standard Deviation
This fund
14.19%
Cat. avg.
14.65%
Lower the better
Sharpe Ratio
This fund
0.79
Cat. avg.
0.55
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Fund Managers
Tanmaya Desai
Since June 2011
Mohit Jain
Since November 2017
Additional Scheme Detailsas of 30th June 2024
ISIN | INF200K01UP2 | Expense Ratio | 0.94% | Exit Load | No Charges | Fund Size | ₹2,760 Cr | Age | 01 Jan 2013 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Withdrawal within 1 year
Flat 15% tax on realised gains (STCG - short term capital gains)
Withdrawal after 1 year
10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)
Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹15.00 Cr | 46.7% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹713.42 Cr | 48.3% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹713.42 Cr | 46.3% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹29.73 Cr | 45.2% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹173.47 Cr | 45.0% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹173.47 Cr | 42.3% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2312.48 Cr | 45.8% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2312.48 Cr | 43.7% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹638.88 Cr | 47.4% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.23 Cr | 44.1% |
About the AMC
Total AUM
₹9,74,502 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Other Funds by SBI Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of SBI Healthcare Opportunities Fund Direct Growth?
What are the returns of SBI Healthcare Opportunities Fund Direct Growth?
What is the portfolio composition of SBI Healthcare Opportunities Fund Direct Growth?
Who manages the SBI Healthcare Opportunities Fund Direct Growth?
- Tanmaya Desai
- Mohit Jain
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.